Press Releases September 15, 2026 07:45 AM

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility

Emergent BioSolutions to Celebrate Expansion and Restart of Canton Manufacturing Facility with Ribbon Cutting Ceremony

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
EBS

Emergent BioSolutions announced a ribbon cutting ceremony on September 16, 2026, to mark the restart and expansion of its manufacturing operations in Canton, Massachusetts. The company is investing in advanced biopharmaceutical manufacturing capabilities, supporting public health preparedness, and creating approximately 50 new skilled jobs in the region. This investment strengthens domestic production in critical health-related sectors and underlines the firm’s commitment to biotechnology growth in Massachusetts.

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
EBS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Emergent BioSolutions is restarting and expanding its Canton, MA biopharmaceutical manufacturing facility.
  • The company plans to create approximately 50 new manufacturing, technical, and operational jobs, boosting the local skilled workforce.
  • The investment supports public health preparedness by enhancing domestic biopharmaceutical manufacturing capabilities, focusing on health threats such as smallpox, mpox, and Ebola.
  • Company leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing

CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility and the company’s investment in the future of advanced biopharmaceutical manufacturing in the Commonwealth.

The event will highlight Emergent's commitment to strengthening domestic manufacturing capabilities, supporting public health preparedness and creating opportunities for skilled jobs in Massachusetts. Emergent plans to add approximately 50 manufacturing, technical and operational positions as part of its investment in the site.

Emergent's investment supports growth in Massachusetts' biotechnology sector while helping build a skilled workforce for the future of advanced manufacturing.

Media Coverage Information
Following the ceremony, media will have the opportunity to speak with company representatives.

Speakers

  • Joe Papa, president and chief executive officer, Emergent
  • Bill Hartzel, senior vice president, manufacturing and bioservices, Emergent
  • Secretary Eric Paley, secretary, executive office of economic development
  • Senator Paul Feeney, Massachusetts Senate
  • Representative William Galvin, Massachusetts House of Representatives

Date/Time
Wednesday, September 16 at 10:00 am ET 

Please arrive no later than 9:45 a.m. to allow time for security screening.

Address
Emergent Canton
90 Shawmut Road, Canton, MA 02021 

Visuals

  • Ceremonial ribbon cutting
  • Executive remarks
  • Group photos with company and state leaders

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Media RSVP:
Alicia Conners
Senior Director, Corporate Communications
mediarelations@ebsi.com


Risks

  • Potential operational challenges or delays in ramping up the manufacturing facility could impact timelines and expected benefits.
  • Changing public health policies or government funding priorities may affect demand for certain biopharmaceutical products.
  • Competition in the biotechnology and advanced manufacturing sectors could impact market share and profitability.

More from Press Releases

Critical Metals Corp. Merger with European Lithium Advances to Shareholder Vote Following Court Ruling Sep 15, 2026 XTEND Expands Global Footprint with New Site in Mexico as Mexico Allocates $17.5 Billion to Defense and Security in 2026¹ Sep 15, 2026 Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics Sep 15, 2026 Safe Harbor to Address Banking and Capital Access for Colorado Cannabis Operators at IgniteIt Market Spotlight 2026 Sep 15, 2026 PolyPid Announces Participation in Upcoming Fall Investor Conferences Sep 15, 2026